Cilostazol/ginkgo-biloba

Drug Profile

Cilostazol/ginkgo-biloba

Alternative Names: Cilostazol/ginkgo-biloba controlled release; Cilostazol/ginkgo-biloba immediate release; Renexin; SID 142

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Chemicals
  • Developer Asan Medical Center; SK Chemicals
  • Class Antiplatelets; Herbal medicines; Neuroprotectants; Small molecules; Tetrazoles; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Ear disorders; Peripheral arterial disorders
  • Phase I Arterial occlusive disorders

Most Recent Events

  • 14 Feb 2016 SK Chemicals terminates phase III trial in Recurrent Vestibulopathy in South Korea (PO, Immediate release) (NCT01895400)
  • 01 Jul 2015 SK Chemicals completes a phase I trial in Arterial occlusive disorders in South Korea (PO, Controlled release) (NCT02625714)
  • 01 Jun 2015 Phase-I clinical trials in Arterial occlusive disorders in South Korea (PO, Controlled release) (NCT02625714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top